Ali-Jackson Kamil
- SEC CIK
- 0001654337
In the past year, 2 open-market sale filings worth $160.4K and no purchases.
Current role at each company
- RIGL Rigel Pharmaceuticals IncDirectoras of Jun 24, 2026
- PDSB PDS Biotechnology CorpDirectoras of Mar 3, 2026
- ACRS Aclaris Therapeutics, Inc.Chief Legal Officeras of Jan 5, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $160.4K
- 2 filings
- Net
- −$160.4K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Ali-Jackson Kamil as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
RIGL Rigel Pharmaceuticals Inc
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Ali-Jackson KamilDirector | SSale | −2.50K | $35.00 | −$87.5K | −19.8%10.1K after | 10b5-1 |
| May 28, 2026 (view filing) | May 26 | 2 days | Ali-Jackson KamilDirector | SSale | −2.50K | $29.17 | −$72.9K | −16.5%12.6K after | 10b5-1 |